KOL Views: Three strikes and solanezumab is out – where does Alzheimer’s disease research go from here?

Eli Lilly announced last week that solanezumab will join a growing list of mAbs against beta-amyloid that have been shelved on account of disappointing results, though there are a lot of differing opinions about the significance of the latest Phase III trial. Indeed, optimistic observers say an optimised agent focusing on more appropriate patients with Alzheimer’s disease (AD) will be the key to success while others are ready to give up on the amyloid hypothesis.

To provide FirstWord readers with a better understanding of the significance of the solanezumab results, we are hosting an expert call with a leading key opinion leader later this week.

Key topics that will be discussed during the call include, among other things… how to interpret the Phase III EXPEDITION 3 data, what read-through there is for other mAbs against beta-amyloid and even BACE inhibitors, expectations for future studies of amyloid-targeting agents, and what alternative pathways deserve more attention.

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the amyloid hypothesis and its role in AD research.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.